NCT07218003 2026-03-23
A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4
Rondo Therapeutics
Phase 1 Enrolling by invitation
Clinical Trials
6 trialsNCT07312578 2025-12-31
Nimotuzumab,Camrelizumab, and Neoadjuvant Chemotherapy（nCT） in the Treatment of Esophageal Squamous Cell Carcinoma
Peking University
Phase 2 Enrolling by invitation
NCT07016737 2025-06-12
ESO-Nanjing12
Jiangsu Cancer Institute & Hospital
Phase 3 Enrolling by invitation
NCT06429865 2024-05-28
Cytosponge in Surveillance After Endoscopic Submucosal Dissection for Esophageal Squamous Cell Carcinoma
Changhai Hospital
Phase NA Enrolling by invitation
NCT06303583 2024-03-12
CRIS
Zhejiang Cancer Hospital
Phase 1/2 Enrolling by invitation
NCT06048926 2023-09-21
Carrelizumab Combined With Concurrent Radiotherapy and Chemotherapy for Unresectable Esophageal Squamous Cell Carcinoma
The First Affiliated Hospital with Nanjing Medical University
Phase NA Enrolling by invitation